methimazole and Parkinsonian-Disorders

We investigated the effects of maternal hypothyroidism on forebrain dopaminergic, GABAergic, and serotonergic systems and related behavior in adult rat offspring. Experimental gestational hypothyroidism (EGH) was induced by administering 0.02% methimazole (MMI) to pregnant rats from gestational day 9 to delivery. Neurotransmitter-related protein and gene expression were evaluated in offspring forebrain at postnatal day (P) 120. Exploratory behavior, contextual fear conditioning, locomotion, and 30-day reserpine Parkinson induction were assessed from P75-P120. Protein and gene expression assessments of medial prefrontal cortex showed group differences in dopaminergic, GABAergic, and serotonergic receptors, catabolic enzymes, and transporters. Striatum of MMI offspring showed an isolated decrease in the dopaminergic enzyme, tyrosine hydroxylase. MMI exposure increased GABA and dopamine receptor expression in amygdala. MMI offspring also had decreased state anxiety and poor contextual fear conditioning. We found that baseline locomotion was not changed, but reserpine treatment significantly reduced locomotion only in MMI offspring. Our results indicated that restriction of maternal thyroid hormones reduced dopaminergic, GABAergic, and serotoninergic forebrain components in offspring. Tyrosine hydroxylase deficiency in the striatum may underlie enhanced reserpine induction of Parkinson-like movement in these same offspring. Deficits across different neurotransmitter systems in medial prefrontal cortex and amygdala may underlie decreased state anxiety-like behavior and reduced fear conditioning in offspring, but no changes in trait anxiety-like behavior occurred with maternal MMI exposure. These findings strongly support the hypothesis that adequate delivery of maternal thyroid hormones to the fetus is crucial to the development of the central nervous system critical for emotion and motor regulation.

Topics: Amygdala; Animals; Anxiety; Anxiety Disorders; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Exploratory Behavior; Fear; Female; GABAergic Neurons; Hypothyroidism; Locomotion; Male; Maternal Exposure; Methimazole; Neurotransmitter Agents; Parkinsonian Disorders; Pregnancy; Prenatal Exposure Delayed Effects; Prosencephalon; Rats; Rats, Wistar; Reserpine; Serotonergic Neurons; Thyroid Hormones; Tyrosine 3-Monooxygenase

Parkinson's disease (PD) is a major age-related neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra par compacta (SNpc) and accumulation of aggregated alpha-synuclein in brain areas. Rotenone is a neurotoxin that is routinely used to model PD, thus to help us understand the mechanisms of neural death. Flavin-containing monooxygenase (FMO), usually known as an important hepatic microsomal enzyme like cytochrome P450, was found to play a role in the brain recent years. In our study we aimed to find out the role that FMO might play in PD pathology. Thus we successfully generated rotenone model in primary midbrain dopaminergic neurons and identified the apoptosis of neurons caused by rotenone. We found that in rotenone model of Parkinsonism, the expression/protein level of parkin and FMO1 were decreased accompanied by the activation of caspase 3. Blocking FMO activity by FMO inhibitor methimazole directly caused activation of caspase 3, meanwhile parkin protein level was decreased. Our data indicated that FMO, whose dysfunction could be a reason for the apoptosis of dopaminergic neurons in rotenone model, might be a new clue of pathological proteins in rotenone model of parkinsonism. Meanwhile, it was suggested that parkin function was compromised in neuro-pathological states, thereby further adding to the cellular survival stress.

Topics: Animals; Apoptosis; Caspase 3; Cells, Cultured; Dopaminergic Neurons; Enzyme Activation; Methimazole; Oxygenases; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Ubiquitin-Protein Ligases